. "Appendix J: Biographical Sketches of Committee Members and Staff." New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: The National Academies Press, 2004.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions
trative psychiatry at Norristown. Prior to coming to Penn, Dr. Cornish spent six years with the Johnson & Johnson Family of Companies. He was associate medical direct or at McNeil Pharmaceuticals and later director of Psychiatric Medications at Janssen Pharmaceutica. Dr. Cornish had received a NIDA Scientist Career Development Award for Clinicians, is currently the principal investigator for a NIDA-funded study (RO1) entitled “Naltrexone Treatment of Opioid Dependent Parolees” and for a depot naltrexone study in a recently funded NIDA (P60) Center grant.
Lewis E. Gallant is the executive director of the National Association of State Alcohol and Drug Abuse Directors, Inc. (NASADAD). He had served as president of NASADAD since 1999 and for the prior two years as first vice president. Dr. Gallant came to NASADAD from the Virginia Department of Mental Health, Mental Retardation and Substance Abuse Services (DMHMRSAS), where he held the position of director of the Office of Substance Abuse Services. He was responsible for promoting, monitoring and evaluating the office’s service programs relating to the prevention and treatment of substance abuse problems, and for coordinating such programs within DMHMRSAS and with other public, private and community-based organizations. He earned a Ph.D. in social work, with an emphasis on human services administration at the University of Texas, Arlington.
Shirley Y. Hill is professor of psychiatry at the University of Pittsburgh School of Medicine, with a joint appointment in the departments of psychology and human genetics. Her career has been focused on etiological factors in addiction. Dr. Hill has been a consultant to the World Health Organization, Program on Substance Abuse, served as a consultant to the NIH Division of Research Grants Advisory Committee, and has served on a number of NIH Initial Review Groups (IRG). She has been a member of the Graduate Faculty University of Pittsburgh since 1990 and was a visiting professor (Spinoza Chair) at the University of Amsterdam, Faculty of Medicine in 1994. Dr. Hill serves on the editorial board of Journal of Studies on Alcohol and is a member of several research societies including American Psychopathological Association, International Society for Biomedical Research on Alcoholism, Research Society on Alcoholism, Sigma Xi Scientific Honorary, Society of Biological Psychiatry, Society for Psychophysiological Research and the American College of Neuropharmacology (ACNP). Currently, she is an ACNP Fellow and member of two ACNP committees, Education and Training, and Ethics. She obtained her early training in neurobiology, medicine, and research methodology at Washington University School of Medicine in St. Louis.